TY  - JOUR
A1  - Solimando, Antonio Giovanni
A1  - Krebs, Markus
A1  - Bittrich, Max
A1  - Einsele, Hermann
T1  - The urgent need for precision medicine in cancer and its microenvironment: the paradigmatic case of multiple myeloma
JF  - Journal of Clinical Medicine
N2  - No abstract available
KW  - precision medicine
KW  - multiple myeloma
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288164
SN  - 2077-0383
VL  - 11
IS  - 18
ER  - 
TY  - JOUR
A1  - Solimando, Antonio Giovanni
A1  - Kalogirou, Charis
A1  - Krebs, Markus
T1  - Angiogenesis as therapeutic target in metastatic prostate cancer – narrowing the gap between bench and bedside
JF  - Frontiers in Immunology
N2  - Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC despite promising preclinical and early clinical data. This discrepancy prompted a literature review highlighting the tumor heterogeneity and biological context of Prostate Cancer (PCa). Narrowing the gap between the bench and bedside appears critical for developing novel therapeutic strategies. Searching clinicaltrials.gov for studies examining angiogenesis inhibition in patients with PCa resulted in n=20 trials with specific angiogenesis inhibitors currently recruiting (as of September 2021). Moreover, several other compounds with known anti-angiogenic properties – such as Metformin or Curcumin – are currently investigated. In general, angiogenesis-targeting strategies in PCa include biomarker-guided treatment stratification – as well as combinatorial approaches. Beyond established angiogenesis inhibitors, PCa therapies aiming at PSMA (Prostate Specific Membrane Antigen) hold the promise to have a substantial anti-angiogenic effect – due to PSMA´s abundant expression in tumor vasculature.
KW  - prostate adenocarcinoma
KW  - PCa
KW  - angiogenesis inhibitors
KW  - TKI
KW  - immunotherapy
KW  - tumor microenvironment
KW  - clinical trials
KW  - PSMA
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-263061
SN  - 1664-3224
VL  - 13
ER  - 
TY  - JOUR
A1  - Marquardt, André
A1  - Kollmannsberger, Philip
A1  - Krebs, Markus
A1  - Argentiero, Antonella
A1  - Knott, Markus
A1  - Solimando, Antonio Giovanni
A1  - Kerscher, Alexander Georg
T1  - Visual clustering of transcriptomic data from primary and metastatic tumors — dependencies and novel pitfalls
JF  - Genes
N2  - Personalized oncology is a rapidly evolving area and offers cancer patients therapy options that are more specific than ever. However, there is still a lack of understanding regarding transcriptomic similarities or differences of metastases and corresponding primary sites. Applying two unsupervised dimension reduction methods (t-Distributed Stochastic Neighbor Embedding (t-SNE) and Uniform Manifold Approximation and Projection (UMAP)) on three datasets of metastases (n = 682 samples) with three different data transformations (unprocessed, log10 as well as log10 + 1 transformed values), we visualized potential underlying clusters. Additionally, we analyzed two datasets (n = 616 samples) containing metastases and primary tumors of one entity, to point out potential familiarities. Using these methods, no tight link between the site of resection and cluster formation outcome could be demonstrated, or for datasets consisting of solely metastasis or mixed datasets. Instead, dimension reduction methods and data transformation significantly impacted visual clustering results. Our findings strongly suggest data transformation to be considered as another key element in the interpretation of visual clustering approaches along with initialization and different parameters. Furthermore, the results highlight the need for a more thorough examination of parameters used in the analysis of clusters.
KW  - visual clustering
KW  - t-SNE
KW  - UMAP
KW  - transcriptomic analysis
KW  - cancer
KW  - metastasis
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-281872
SN  - 2073-4425
VL  - 13
IS  - 8
ER  -